Haematology & Oncology News

Start OPDIVO now †

† Access to OPDIVO monotherapy is available now from BMS in line with the Product Information and program eligibility criteria. 1 For further information and enquiries regarding access to OPDIVO, please contact your local BMS representative.

PBS Information: This product is not listed on the PBS

Please refer to the Approved Product Information before prescribing. The Product Information is available upon request from BMS Medical Information Department: 1800 067 567 or can be accessed at http://www.medicines.org.au/files/bqpopdiv.pdf

WARNING: IMMUNE-RELATED ADVERSE REACTIONS WITH OPDIVO AND YERVOY (IPILIMUMAB) COMBINATION THERAPY. Physicians should consult the YERVOY product information prior to initiation of OPDIVO in combination with YERVOY. It is recommended that the combination of OPDIVO and YERVOY should be administered and monitored under the supervision of physicians experienced with the use of immunotherapy in the treatment of unresectable or metastatic melanoma. More frequent, and more serious, immune-related adverse reactions are seen with OPDIVO and YERVOY combination therapy than with the use of single agent nivolumab or ipilimumab. OPDIVO and YERVOY combination therapy can cause a wide range of potentially life-threatening immune-related adverse reactions including pneumonitis, hepatitis, diarrhoea/colitis, rash, hypophysitis and thyroid dysfunction, as well as immune-related adverse reactions in other organ systems. Early diagnosis and appropriate management are essential to minimise life-threatening complications (see PRECAUTIONS, ADVERSE EFFECTS and DOSAGE & ADMINISTRATION). ALK = Anaplastic lymphoma receptor tyrosine kinase; EGFR = Epidermal growth factor receptor; NSCLC = Non-small cell lung cancer. Reference: 1. OPDIVO (nivolumab) Approved Product Information, February 2016. © 2016 Bristol-Myers Squibb. OPDIVO ® is a registered trademark of Bristol-Myers Squibb Company. BMS Medical Information: 1800 067 567. Bristol-Myers Squibb Australia Pty Ltd, ABN 33 004 333 322, 4 Nexus Court, Mulgrave, VIC 3170. NIV/0111/02-16. Date of preparation: February 2016. BMSA0070.